Paolo Tarantino/X
Jun 1, 2025, 00:39
Paolo Tarantino: Very promising data with KAT6 inhibition + fulvestrant
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X:
“Very promising data with KAT6 inhibition + fulvestrant presented by Pat LoRusso. Among 43 pts with HR+/HER2- MBC, all with prior CDK4/6i, ORR was 37%, mPFS 10.7 months. Main toxicity: 74% with dysgeusia (paging Antonio Giordano for the pronunciation of this tox).”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 6, 2025, 18:05
Sep 6, 2025, 17:52
Sep 6, 2025, 17:48
Sep 6, 2025, 17:39
Sep 6, 2025, 17:28
Sep 6, 2025, 15:55
Sep 6, 2025, 15:54